Shattuck Labs, Inc. PE Ratio
The price-to-earnings (P/E) ratio tells you how many dollars investors pay for each dollar of a company's annual profit. It is market capitalization divided by net income over the trailing four quarters, meaning the four most recent filed quarters added together, and the table shows both amounts. A higher P/E means investors are paying more for each dollar of current earnings, often because they expect profits to grow; a negative P/E means the company lost money over those four quarters. Each point uses the filed share count and the last closing price on or before that quarter-end date, never today's price.
- Shattuck Labs, Inc. pe ratio for the quarter ending 2026-06-30 was -13.3, a change of -12.68 year-over-year.
- Shattuck Labs, Inc. pe ratio for the quarter ending 2026-03-31 was -9.76, a change of -9.12 year-over-year.
- Shattuck Labs, Inc. pe ratio for the quarter ending 2025-12-31 was -4.72, a change of -3.95 year-over-year.
- Shattuck Labs, Inc. pe ratio for the quarter ending 2025-09-30 was -2.71, a change of -0.48 year-over-year.
- Shattuck Labs, Inc. pe ratio for fiscal 2026 was -13.3.
- Shattuck Labs, Inc. pe ratio for fiscal 2025 was -4.72, a change of -3.95 from fiscal 2024.
- Shattuck Labs, Inc. pe ratio for fiscal 2024 was -0.77, a change of 3.09 from fiscal 2023.
- Shattuck Labs, Inc. pe ratio for fiscal 2023 was -3.86, a change of -2.9 from fiscal 2022.
- Available history
- 2020-12-31 to 2026-06-30
- Data captured
Historical PE Ratio
Annual PE Ratio
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |